BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 31647984)

  • 1. Role of Age and Hematopoietic Cell Transplantation-Specific Comorbidity Index in Myelodysplastic Patients Undergoing an Allotransplant: A Retrospective Study from the Chronic Malignancies Working Party of the European Group for Blood and Marrow Transplantation.
    Carré M; Porcher R; Finke J; Ehninger G; Koster L; Beelen D; Ganser A; Volin L; Lozano S; Friis L; Michallet M; Tischer J; Olavarria E; Cascon MJP; Iacobelli S; Koc Y; Jindra P; Arat M; de Witte T; Yakoub Agha I; Kröger N; Robin M
    Biol Blood Marrow Transplant; 2020 Mar; 26(3):451-457. PubMed ID: 31647984
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of Risk Scoring Systems in HLA-Matched Related Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Cohort Study.
    Aladağ E; Demiroğlu H; Büyükaşık Y; Göker H
    Turk J Haematol; 2021 Jun; 38(2):138-144. PubMed ID: 32539316
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does the hematopoietic cell transplantation specific comorbidity index (HCT-CI) predict transplantation outcomes? A prospective multicenter validation study of the Kanto Study Group for Cell Therapy.
    Nakaya A; Mori T; Tanaka M; Tomita N; Nakaseko C; Yano S; Fujisawa S; Sakamaki H; Aotsuka N; Yokota A; Kanda Y; Sakura T; Nanya Y; Saitoh T; Kanamori H; Takahashi S; Okamoto S
    Biol Blood Marrow Transplant; 2014 Oct; 20(10):1553-9. PubMed ID: 25034961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of Pretransplantation Prediction Models for Nonrelapse Mortality in Patients with Myelofibrosis Undergoing Allogeneic Stem Cell Transplantation.
    Acosta-Medina AA; Baranwal A; Johnson IM; Kharfan-Dabaja MA; Murthy H; Palmer JM; Sproat L; Mangaonkar A; Shah MV; Hogan WJ; Litzow MR; Tefferi A; Alkhateeb HB
    Transplant Cell Ther; 2023 Jun; 29(6):360.e1-360.e8. PubMed ID: 36773650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: the flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC.
    Barba P; Piñana JL; Martino R; Valcárcel D; Amorós A; Sureda A; Briones J; Delgado J; Brunet S; Sierra J
    Biol Blood Marrow Transplant; 2010 Mar; 16(3):413-20. PubMed ID: 19922807
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hematopoietic cell transplant comorbidity index is predictive of survival after autologous hematopoietic cell transplantation in multiple myeloma.
    Saad A; Mahindra A; Zhang MJ; Zhong X; Costa LJ; Dispenzieri A; Drobyski WR; Freytes CO; Gale RP; Gasparetto CJ; Holmberg LA; Kamble RT; Krishnan AY; Kyle RA; Marks D; Nishihori T; Pasquini MC; Ramanathan M; Lonial S; Savani BN; Saber W; Sharma M; Sorror ML; Wirk BM; Hari PN
    Biol Blood Marrow Transplant; 2014 Mar; 20(3):402-408.e1. PubMed ID: 24342394
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hematopoietic Cell Transplantation-Specific Comorbidity Index Predicts Morbidity and Mortality in Autologous Stem Cell Transplantation.
    Berro M; Arbelbide JA; Rivas MM; Basquiera AL; Ferini G; Vitriu A; Foncuberta C; Fernandez Escobar N; Requejo A; Milovic V; Yantorno S; Szelagoswki M; Martinez Rolon J; Bentolila G; Garcia JJ; Garcia P; Caeiro G; Castro M; Jaimovich G; Palmer S; Trucco JI; Bet LA; Shaw BE; Kusminsky GD
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1646-1650. PubMed ID: 28669923
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validation of the Hematopoietic Cell Transplantation-Specific Comorbidity Index in Nonmyeloablative Allogeneic Stem Cell Transplantation.
    Veeraputhiran M; Yang L; Sundaram V; Arai S; Lowsky R; Miklos D; Meyer E; Muffly L; Negrin R; Rezvani A; Shizuru J; Weng WK; Johnston L
    Biol Blood Marrow Transplant; 2017 Oct; 23(10):1744-1748. PubMed ID: 28668491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Promising Outcome of Umbilical Cord Blood Transplantation in Patients with Multiple Comorbidities.
    Adachi Y; Ukai S; Sagou K; Fukushima N; Ozeki K; Kohno A
    Biol Blood Marrow Transplant; 2018 Jul; 24(7):1455-1462. PubMed ID: 29476952
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hematopoietic Cell Transplantation Comorbidity Index Predicts Outcomes in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes Receiving CD34
    Barba P; Ratan R; Cho C; Ceberio I; Hilden P; Devlin SM; Maloy MA; Barker JN; Castro-Malaspina H; Jakubowski AA; Koehne G; Papadopoulos EB; Ponce DM; Sauter C; Tamari R; van den Brink MRM; Young JW; O'Reilly RJ; Giralt SA; Perales MA
    Biol Blood Marrow Transplant; 2017 Jan; 23(1):67-74. PubMed ID: 27789361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Prognostic implications of hematopoietic cell transplantation-specific comorbidity index on non-relapse mortality and overall survival after allogeneic hematopoietic stem cell transplantation].
    Wang CY; Ren HY; Qiu ZX; Wang Y; Cen XN; Wang LH; Wang MJ; Xu WL; Wang WS; Li Y; Dong YJ; Ou JP; Liang ZY; Liu W; Wang Q
    Zhonghua Xue Ye Xue Za Zhi; 2013 Aug; 34(8):659-63. PubMed ID: 23978015
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modified EBMT risk score and the hematopoietic cell transplantation-specific comorbidity index for pre-transplant risk assessment in adult acute lymphoblastic leukemia.
    Terwey TH; Hemmati PG; Martus P; Dietz E; Vuong LG; Massenkeil G; Dörken B; Arnold R
    Haematologica; 2010 May; 95(5):810-8. PubMed ID: 20007143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of HCT-comorbidity index, age and disease status at transplantation in predicting survival and non-relapse mortality in patients with myelodysplasia and leukemia undergoing reduced-intensity-conditioning hemopoeitic progenitor cell transplantation.
    Bokhari SW; Watson L; Nagra S; Cook M; Byrne JL; Craddock C; Russell NH
    Bone Marrow Transplant; 2012 Apr; 47(4):528-34. PubMed ID: 21743502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination of the Hematopoietic Cell Transplantation Comorbidity Index and the European Group for Blood and Marrow Transplantation score allows a better stratification of high-risk patients undergoing reduced-toxicity allogeneic hematopoietic cell transplantation.
    Barba P; Martino R; Pérez-Simón JA; Fernández-Avilés F; Castillo N; Piñana JL; López-Anglada L; Rovira M; Bosch F; Carreras E; Corral LL; Sierra J; Valcárcel D
    Biol Blood Marrow Transplant; 2014 Jan; 20(1):66-72. PubMed ID: 24141006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Assessment in Adult T Cell Leukemia/Lymphoma Treated with Allogeneic Hematopoietic Stem Cell Transplantation.
    Yoshimitsu M; Tanosaki R; Kato K; Ishida T; Choi I; Takatsuka Y; Fukuda T; Eto T; Hidaka M; Uchida N; Miyamoto T; Nakashima Y; Moriuchi Y; Nagafuji K; Miyazaki Y; Ichinohe T; Takanashi M; Atsuta Y; Utsunomiya A;
    Biol Blood Marrow Transplant; 2018 Apr; 24(4):832-839. PubMed ID: 29155320
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cardiopulmonary Exercise Test With Comorbidity Index Before Allogeneic Hematopoietic Stem Cell Transplantation.
    Yeon SH; Lee MW; Duong TT; Kang S; Jee S; Ahn SY; Ryu H; Lee HJ; Kwon JH; Yun HJ; Jo DY; Song IC
    Integr Cancer Ther; 2022; 21():15347354221134249. PubMed ID: 36398897
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baseline Renal Function and Albumin are Powerful Predictors for Allogeneic Transplantation-Related Mortality.
    Shouval R; de Jong CN; Fein J; Broers AEC; Danylesko I; Shimoni A; Reurs MR; Baars AE; van der Schaft N; Nagler A; Cornelissen JJ
    Biol Blood Marrow Transplant; 2018 Aug; 24(8):1685-1691. PubMed ID: 29753163
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adapting the HCT-CI Definitions for Children, Adolescents, and Young Adults with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation.
    Friend BD; Broglie L; Logan BR; Chhabra S; Bupp C; Schiller G; Beitinjaneh A; Perez MAD; Guilcher GMT; Hashem H; Hildebrandt GC; Krem MM; Lazarus HM; Nishihori T; Nusrat R; Rotz SJ; Wirk B; Wieduwilt M; Pasquini M; Savani BN; Stadtmauer EA; Sorror ML; Thakar MS
    Transplant Cell Ther; 2023 Feb; 29(2):123.e1-123.e10. PubMed ID: 36442769
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The hematopoietic cell transplantation comorbidity index (HCT-CI) predicts clinical outcomes in lymphoma and myeloma patients after reduced-intensity or non-myeloablative allogeneic stem cell transplantation.
    Farina L; Bruno B; Patriarca F; Spina F; Sorasio R; Morelli M; Fanin R; Boccadoro M; Corradini P
    Leukemia; 2009 Jun; 23(6):1131-8. PubMed ID: 19194465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of comorbidities constituting the hematopoietic cell transplant (HCT)-comorbidity index on the outcome of patients undergoing allogeneic HCT for acute myeloid leukemia.
    Khalil MMI; Lipton JH; Atenafu EG; Gupta V; Kim DD; Kuruvilla J; Viswabandya A; Messner HA; Michelis FV
    Eur J Haematol; 2018 Feb; 100(2):198-205. PubMed ID: 29168234
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.